Nautilus Biotechnology is trading at $2.60, up 6.62%, following its October 27, 2026 report of a Q3 loss of $0.12 per share, narrower than the $0.14 analyst estimate. - The company announced participation in an ARPA-H-funded research consortium, with up to $6 million expected for Voyager platform work on Alzheimer’s disease and Ewing sarcoma proteoforms. - Recent closes show considerable volatility, including a 24.69% decline on October 26.